Romosozumab associated with bone density increase

Article

Results of a Phase II study suggest that romosozumab significantly increases bone mineral density (BMD) in the lumbar spine, total hip, and femoral neck. Exploratory analyses showed the BMD increases in the lumbar spine and hip were significantly higher with romosozumab than alendronate sodium and teriparatide in postmenopausal women with low BMD.

 

 

 

Results of a Phase II study suggest that romosozumab significantly increases bone mineral density (BMD) in the lumbar spine, total hip, and femoral neck. Exploratory analyses showed the BMD increases in the lumbar spine and hip were significantly higher with romosozumab than alendronate sodium and teriparatide in postmenopausal women with low BMD.

Researchers from the Oregon Osteoporosis Center evaluated the efficacy of romosozumab for a 12-month period in 419 women aged 55 to 85 years of age who had low BMD (T score -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the 3 sites). Participants were randomly assigned to monthly romosozumab (a dose of 70 mg, 140 mg, or 210 mg) or romosozumab every 3 months (a dose of 140 mg or 210 mg) administered subcutaneously; subcutaneous placebo; or an open-label active comparator – oral alendronate (70 mg) administered weekly or subcutaneous teriparatide (20 μg) administered daily.

The investigators found that all dosage levels of romosozumab were associated with significant BMD increases at the lumbar spine, an increase of 11.3% with the 210 mg monthly dose. In comparison, teriparatide resulted in an increase of 7.1% and alendronate in an increase of 4.1%. BMD decreased 0.1% in the comparator group. Romosozumab was also associated with significant increases in BMD at the total hip and femoral neck, transitory increases in bone-formation markers, and sustained descreases in a bone-resorption marker. Adverse effects were mild across all dosage groups, with the most common being mild, generally nonrecurring injection-site reactions.

The scientists concluded that romosozumab was associated with increased BMD and bone formation in postmenopausal women.

 

 

 

To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.